Uncovering the Impact of Moderate COPD Exacerbations
Pulmonology
Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid
Dermatology
Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
ERS 2024 | Living With COPD: Linking Inflammation with PatientBurden
Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
Dermatology
Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria
Dermatology
Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema
Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management
Dermatology
A review of disease burden and treatment needs in PN and CSU, and how current and emerging therapies can impact patient management in these respective diseases.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
